A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease

Conclusions Vonoprazan 10mg and 20mg are not superior to placebo with respect to proportion of days without heartburn whereas the mean severity of heartburn is lower with vonoprazan compared with placebo in patients with NERD. Registration ClinicalTrials.gov: NCT01474369 Funding Takeda Pharmaceutical Company Limited
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research